Topic
1 story, newest first.
A UK-led trial of a tetanus-diphtheria vaccine that does not require refrigeration has reported 100% protective antibody levels in all participants. The vaccine, SPVX02, remained stable at 30°C for at least two years, addressing cold-chain failures that waste millions of doses annually.
